| Purpose | AGM Date | Announcement Date |
|---|---|---|
| AGM | 18 Sep 2025 | 26 Aug 2025 |
| Senores Pharmaceuticals Limited has informed the exchange regarding Notice of Eighth (8th) Annual General Meeting to be held on September 18, 2025 at 11:30 AM (IST) through VC/OAVM Senores Pharmaceuticals Limited has informed the exchange regarding submission of Annual Report for the Financial Year 2024-25 (As per BSE Announcement dated on: 26.08.2025) Senores Pharmaceuticals Limited has informed the Exchange regarding the proceedings of the 08th Annual General Meeting of the Company. (As per BSE Announcement Dated on 18/09/2025) | ||
The acquisition will be carried out in two tranches and has received approval from the management committee of the company’s board.
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Senores Pharmaceuticals shares closed 6% below their listing price, although they are still up 43% from the IPO price.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.